ASO Visual Abstract: Comparison between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate/Advanced-Stage Hepatocellular Carcinoma

Yangxun Pan(Sun Yat-sen University), Li Xu(Fujian Medical University), Yaojun Zhang(Sun Yat-sen University), Minjiang Yi(Sun Yat-sen University), Zhongguo Zhou(Sun Yat-sen University), Jinbin Chen(Sun Yat-sen University), Deyao Zhang(Sun Yat-sen University), Xiaohui Wang(Hong Kong Baptist University), Juncheng Wang(Sun Yat-sen University), Minshan Chen(Sun Yat-sen University), Jie Mei(Sun Yat-sen University), Rong Guo(Sun Yat-sen University)
Annals of Surgical Oncology
October 21, 2021
10.1245/s10434-021-10970-7
Cited by 0

Related Papers

Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216
Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis
|Journal of Clinical Investigation|2018|190